Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression
Paper by Antoine Italiano indexed on Europe PMC as PubMed record 35118423, in Nature Cancer (2021), one of the most cited records naming an author with this name at Institut Bergonié.
Overview
Only a minority of patients derive long-term clinical benefit from anti-PD1/PD-L1 monoclonal antibodies. The presence of tertiary lymphoid structures (TLS) has been associated with improved survival in several tumor types. Here, using a large-scale retrospective analysis of three independent cohorts of cancer patients treated with anti-PD1/PD-L1 antibodies, we showed that the presence of mature TLS was associated with improved objective response rate, progression-free survival, and overall survival independently of PD-L1 expression status and CD8+ T-cell density. These results pave the way for using TLS detection to select patients who are more likely to benefit from immune checkpoint blockade.
Indexed on Europe PMC as PubMed record 35118423 (DOI 10.1038/s43018-021-00232-6). Its author list gives "Italiano A" with the affiliation "Department of Medicine, Institut Bergonié, Bordeaux, France", which names Institut Bergonié; that is how the record was matched to Antoine Italiano, and no figure has been checked by an editor.
One of the most cited papers Europe PMC returns for Antoine Italiano at Institut Bergonié, so it is a natural starting point for reading their work. The record was linked automatically from the author list and affiliation; read the abstract above and the paper itself before relying on any figure.
- Matched to the person by surname, initials and an affiliation string naming the institution on the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.
- Two authors sharing a surname, initials and institution cannot be told apart by this method; the person's profile links are the place to confirm authorship.